Archford Capital Strategies LLC Acquires Shares of 2,019 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Archford Capital Strategies LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 2,019 shares of the biopharmaceutical company’s stock, valued at approximately $545,000.

Other hedge funds have also modified their holdings of the company. Truist Financial Corp increased its holdings in Alnylam Pharmaceuticals by 136.6% in the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock worth $1,035,000 after buying an additional 2,539 shares during the last quarter. IFP Advisors Inc increased its stake in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 47 shares during the last quarter. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $243,000. Silvercrest Asset Management Group LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth $1,151,000. Finally, Blue Trust Inc. increased its stake in shares of Alnylam Pharmaceuticals by 33.9% during the 1st quarter. Blue Trust Inc. now owns 1,158 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 293 shares during the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Down 0.9%

ALNY stock opened at $321.94 on Thursday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $205.87 and a twelve month high of $326.03. The company has a market cap of $41.98 billion, a PE ratio of -154.04 and a beta of 0.22. The business’s 50-day simple moving average is $282.80 and its 200 day simple moving average is $262.36. The company has a quick ratio of 2.98, a current ratio of 3.04 and a debt-to-equity ratio of 8.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. The firm had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same period in the previous year, the business posted ($0.16) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 20.2% compared to the same quarter last year. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

ALNY has been the topic of several analyst reports. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Royal Bank Of Canada increased their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a report on Friday, March 21st. Citigroup increased their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a report on Friday, March 21st. JPMorgan Chase & Co. increased their price target on Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the company an “overweight” rating in a report on Thursday, June 12th. Finally, Stifel Nicolaus raised their target price on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a “buy” rating in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $335.32.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00. Following the sale, the chief executive officer now directly owns 48,948 shares of the company’s stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.